 |
Abdom Radiol (NY)
- YAGI F, Akita H, Matsumoto K, Kosaka T, et al
A case of plasmacytoid urothelial carcinoma with characteristic radiological
findings.
Abdom Radiol (NY). 2025;50:5376-5381.
PubMed
Abstract available
ACS Nano
- YAN Y, Ahmed M, Mach KE, Liao JC, et al
An Organoid Biosensing Platform for Personalized Prognosis of Bladder Cancer.
ACS Nano. 2025 Oct 30. doi: 10.1021/acsnano.5c09883.
PubMed
Abstract available
Adv Mater
- WU Y, Zhang Y, Han J, Jiang Y, et al
Nanozyme-Based Biomimetic Intelligent Immune Organelles for the Treatment of
Bladder-Metastasized Tumors.
Adv Mater. 2025;37:e11181.
PubMed
Abstract available
Adv Sci (Weinh)
- CUI S, Luo X, Fan G, Jiang J, et al
A Novel FGFR3-Targeting Antibody-Drug Conjugate Induces Tumor Cell Apoptosis
through the cGAS-STING Pathway in Bladder Cancer.
Adv Sci (Weinh). 2025 Oct 30:e09933. doi: 10.1002/advs.202509933.
PubMed
Abstract available
Ann Surg Oncol
- ZHU X, Liao D, Huang S, Feng Y, et al
Letter to the Editor Regarding "Assessing the Influence of Bladder Cancer on
Upper Tract Urothelial Carcinoma Prognoses Following Radical Nephroureterectomy:
A Retrospective, Propensity Score-Based Multicenter Cohort Study".
Ann Surg Oncol. 2025 Oct 25. doi: 10.1245/s10434-025-18611.
PubMed
Anticancer Res
- DELL'ATTI L
Management of Bladder Cancer During Pregnancy: A Narrative Review.
Anticancer Res. 2025;45:4689-4695.
PubMed
Abstract available
ANZ J Surg
- PAU S, Patel A, Yap S, Eglinton T, et al
Colovesical Fistula Management and the Role of Cystoscopy: A Single Institution
Experience.
ANZ J Surg. 2025;95:2148-2154.
PubMed
Abstract available
Asian Pac J Cancer Prev
- GOTI V, Raza MW, Singh A, Prasad SN, et al
A Phase 2 Prospective Trial of Capecitabine Plus Oxaliplatin as First-Line
Therapy for Advanced Gall Bladder Cancers.
Asian Pac J Cancer Prev. 2025;26:3761-3767.
PubMed
Abstract available
Beijing Da Xue Xue Bao Yi Xue Ban
- LI S, Su D, Lin J, Song H, et al
[Prognostic analysis of laparoscopic simultaneous radical cystectomy and
nephroureterectomy].
Beijing Da Xue Xue Bao Yi Xue Ban. 2025;57:961-966.
PubMed
Abstract available
Bladder Cancer
- DYRSKJOT L, Black P, Lerner S, Theodorescu D, et al
Bladder cancer journal as official IBCN partner; strengthening global
collaboration in bladder cancer.
Bladder Cancer. 2025;11:23523735251384859.
PubMed
BMC Cancer
- ZHENG J, Lu S, Zhang Q, Zhang L, et al
Development and external validation of a FISH-clinical nomogram for predicting
overall survival in bladder cancer patients after radical cystectomy.
BMC Cancer. 2025;25:1648.
PubMed
Abstract available
BMC Pharmacol Toxicol
- MING J, Jin S, Liu Z, Yang K, et al
Imidacloprid contributes to bladder cancer progression: preliminary evidence
based on network toxicology, machine learning and molecular docking.
BMC Pharmacol Toxicol. 2025;26:180.
PubMed
Abstract available
BMC Urol
- AYDIN R, Ergul RB, Tantekin A, Sanli Y, et al
The utility of radiopharmaceutical uptake in the bladder neck and prostate on
preoperative FDG PET/CT in determining urethral surgical margin positivity in
patients undergoing radical cystoprostatectomy for bladder cancer.
BMC Urol. 2025;25:271.
PubMed
Abstract available
- LIN S, Jiang Y, Xu T, Zhou X, et al
The incidence and risk factors of urinary tract infections in patients undergoing
bladder tumor resection: a systematic review and meta-analysis.
BMC Urol. 2025;25:267.
PubMed
Abstract available
Cancer Causes Control
- CHOKUNONGA E, Borok M, Danso AP, Chirenje M, et al
Trends in the incidence of cancers of the male genital system and urinary bladder
in Harare, Zimbabwe, 1990-2019.
Cancer Causes Control. 2025;36:1579-1587.
PubMed
Abstract available
Cancer Cell Int
- QIAN C, Qin J, Lin Z, Wang S, et al
Single-cell stemness analysis highlights Midkine-LRP1 pathway and identifies new
bladder cancer subtypes.
Cancer Cell Int. 2025;25:376.
PubMed
Abstract available
Cancer Gene Ther
- COLSON M, Aubry A, Gaide N, Lluel P, et al
Bacterial nanoparticles as a potent and safe alternative to BCG for bladder
cancer immunotherapy.
Cancer Gene Ther. 2025 Oct 30. doi: 10.1038/s41417-025-00984.
PubMed
Abstract available
Cancer Genomics Proteomics
- IDE H, Najafi MAE, Matsukawa T, Tatenuma T, et al
Expression of Glucocorticoid Receptor and FOXO1/phospho-FOXO1 in Bladder Cancer
as Independent Prognosticators.
Cancer Genomics Proteomics. 2025;22:850-862.
PubMed
Abstract available
Cancer Med
- NAGATA M, Kikuchi E, Ito T, Sato M, et al
Avelumab Maintenance Therapy in Patients With Curatively Unresectable Urothelial
Carcinoma in Japan: Subgroup Analyses of Post-Marketing Surveillance Data by Age,
Prior Chemotherapy Regimen, and Best Overall Response to Prior Chemotherapy.
Cancer Med. 2025;14:e71177.
PubMed
Abstract available
- KIKUCHI E, Nagata M, Ito T, Sato M, et al
Real-World Outcomes of Avelumab Maintenance Therapy in Patients With Curatively
Unresectable Urothelial Carcinoma in Japan: Results From the Final Analysis of
Postmarketing Surveillance.
Cancer Med. 2025;14:e71264.
PubMed
Abstract available
Cancer Sci
-
EXPRESSION OF CONCERN: Long Non-coding RNA Urothelial Cancer-associated 1
Promotes Bladder Cancer Cell Migration and Invasion by Way of the
hsa-miR-145-ZEB1/2-FSCN1 Pathway.
Cancer Sci. 2025 Oct 29. doi: 10.1111/cas.70241.
PubMed
Cancers (Basel)
- OZTAN G, Issever H, Issever T, Sahin L, et al
Lead Exposure and Bladder Cancer: Molecular Insights from TCGA RNA-Seq and
Toxicogenomic Integration.
Cancers (Basel). 2025;17:3291.
PubMed
Abstract available
Cell Death Dis
- CAI Y, Zhu C, Shi MH, Zhang JH, et al
YTHDC2 suppresses bladder cancer by inhibiting SOX2-mediated tumor plasticity.
Cell Death Dis. 2025;16:765.
PubMed
Abstract available
Clin Genitourin Cancer
- SOLIMAN A, Murad MR, Jabrieh G, AlEdani EM, et al
A Systematic Review and Meta-Analysis of the Effectiveness and Safety of Immune
Checkpoint Inhibitors in Patients With BCG-Unresponsive Non-Muscle-Invasive
Bladder Cancer.
Clin Genitourin Cancer. 2025 Sep 25:102445. doi: 10.1016/j.clgc.2025.102445.
PubMed
Abstract available
Clin Interv Aging
- CHOI J, Park C, Lee KH, Kwak HJ, et al
Comparison of Remimazolam and Sevoflurane on Perioperative Body Temperature
Changes in Older Patients Undergoing Transurethral Resection of Prostate or
Bladder Tumors Under General Anesthesia: A Randomized Prospective Clinical Trial.
Clin Interv Aging. 2025;20:1811-1820.
PubMed
Abstract available
Clin Transl Oncol
- PUENTE J, Rodriguez-Vida A, Sevillano E, Estevez SV, et al
SEOM-SOGUG clinical guideline for urothelial cancer (2025).
Clin Transl Oncol. 2025;27:4142-4159.
PubMed
Abstract available
Clinicoecon Outcomes Res
- SHIH V, Yin L, Theodorou E, Dillon R, et al
A Systematic Literature Review of Real-World Treatment Effectiveness and Economic
and Humanistic Burden in Patients With Muscle-Invasive Bladder Cancer Who
Underwent Radical Cystectomy.
Clinicoecon Outcomes Res. 2025;17:729-742.
PubMed
Abstract available
Cureus
- OKUR A, Sahin KC, Sahin Z, Gultekin MH, et al
Leser-Trelat Sign as an Initial Manifestation of Synchronous Prostate and Bladder
Cancer.
Cureus. 2025;17:e93325.
PubMed
Abstract available
Curr Oncol
- EREN AE, Aydin AA, Aksaray EE, Durak A, et al
Pan-Immune-Inflammation Value as a Predictor of Long-Term Outcomes in Patients
with Urothelial Carcinoma of the Bladder: A Pilot Study.
Curr Oncol. 2025;32:534.
PubMed
Abstract available
Diabetes Res Clin Pract
- BENNETT HO, Bogumil D, Kysh L, van den Brandt P, et al
Systematic review and meta-analysis corrected for history of smoking tobacco
identifies type 1 diabetes as a possible risk factor for bladder cancer.
Diabetes Res Clin Pract. 2025 Oct 29:112976. doi: 10.1016/j.diabres.2025.112976.
PubMed
Abstract available
Eur Urol
- DREYER T, Jensen JB
Reply to Behzad Jazayeri, Xuefeng Wang, and Roger Li's Letter to the Editor re:
Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer
Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade
Non-muscle-invasive B
Eur Urol. 2025 Oct 23:S0302-2838(25)04739-6. doi: 10.1016/j.eururo.2025.
PubMed
Eur Urol Focus
- MONTORSI F, Moschini M, Rosiello G, Gandaglia G, et al
Re: Siamak Daneshmand, Michiel S. Van der Heijden, Joseph M. Jacob, et al.
TAR-200 for Bacillus Calmette-Guerin-unresponsive High-risk Non-muscle-invasive
Bladder Cancer: Results from the Phase IIb SunRISe-1 Study. J Clin Oncol. In
press. https://doi.
Eur Urol Focus. 2025 Oct 25:S2405-4569(25)00286.
PubMed
- WONG R, Matulewicz RS, Bjurlin MA
A Urologist's Guide to Managing Bladder Cancer in Patients Who Smoke.
Eur Urol Focus. 2025 Oct 27:S2405-4569(25)00287.
PubMed
Abstract available
Eur Urol Oncol
- GUERRERO-RAMOS F, Schwenke C, Pinto A, Mulhern-Haughey S, et al
Systematic Review of the Definition of Cure and of Curative-intent Treatments in
Early Bladder Cancer.
Eur Urol Oncol. 2025 Oct 30:S2588-9311(25)00256.
PubMed
Abstract available
Front Oncol
- BAKULA M, Hudolin T, Kulis T, Zekulic T, et al
Sequential intravesical Bacillus Calmette-Guerin and mitomycin C applied with
electromotive drug administration therapy for non-muscle invasive bladder cancer.
Front Oncol. 2025;15:1682918.
PubMed
Abstract available
Front Surg
- MENG R, Han Y, Zhai Z
Analysis of risk factors for ureteral stricture and tumor recurrence after
transurethral resection of bladder tumor in paraureteral bladder cancer.
Front Surg. 2025;12:1680837.
PubMed
Abstract available
Genes (Basel)
- WU J, Liu W
Integrative Analysis of Biomarkers for Cancer Stem Cells in Bladder Cancer and
Their Therapeutic Potential.
Genes (Basel). 2025;16:1146.
PubMed
Abstract available
In Vivo
- CHEN KP, Liao TL, Hsu FT, Chen GH, et al
miR-124 Targets EGFR and Attenuates Growth and Invasion in Bladder Cancer Cells.
In Vivo. 2025;39:3216-3225.
PubMed
Abstract available
- GAMBALE E, Giorgione R, Basso U, Galli L, et al
A Snapshot from the Italian Clinical Practice Regarding Efficacy and Utility Rate
of Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: The RealBLADDER
Study.
In Vivo. 2025;39:3381-3393.
PubMed
Abstract available
Indian J Pathol Microbiol
- KAUR N, Khanna M, Kaur A, Gill KS, et al
The expression of p53 in urothelial carcinoma of bladder: An immunohistochemical
study.
Indian J Pathol Microbiol. 2025;68:492-497.
PubMed
Abstract available
Int J Clin Oncol
- MATSUMURA N, Mandai M
PMDA regulatory update on approval and revision of the precautions for use of
anticancer drugs in Japan; durvalumab, cemiplimab, zongertinib, and taletrectinib
for lung cancer, pirtobrutinib and atezolizumab for lymphoma, durvalumab for
bladder cancer
Int J Clin Oncol. 2025 Oct 25. doi: 10.1007/s10147-025-02901.
PubMed
- NAGUMO Y, Mathis BJ, Nishiyama H
First-line treatment options for metastatic urothelial carcinoma: balancing
efficacy, safety, and individual values and preferences through shared decision
making.
Int J Clin Oncol. 2025;30:2161-2167.
PubMed
Abstract available
Int J Radiat Oncol Biol Phys
- HASSAN N, Michaud E, Mansure JJ, Farag M, et al
The clinical relevance of tertiary lymphoid structures in assessing treatment
response in muscle invasive bladder cancer.
Int J Radiat Oncol Biol Phys. 2025 Oct 22:S0360-3016(25)06329.
PubMed
Abstract available
Int J Surg
- SUN Y, Liu X, He W
Comment on "Correlation of noninvasive imaging of tumour-infiltrating lymphocytes
with survival and BCG immunotherapy response in patients with bladder cancer: a
multicentre cohort study".
Int J Surg. 2025 Oct 28. doi: 10.1097/JS9.0000000000003680.
PubMed
Int Urol Nephrol
- HONG T, Zhao C, Ji H, Chen H, et al
Bladder-sparing therapy for high-tumor-burden non-muscle invasive bladder cancer:
outcomes from high-tumor-burden NMIBC program.
Int Urol Nephrol. 2025 Oct 28. doi: 10.1007/s11255-025-04873.
PubMed
Abstract available
J Extracell Vesicles
- HUANG CS, Yu DS, Jiang SS, Wu YS, et al
Extracellular Vesicle-Mediated Regulation of H3C14 Contributes to Gemcitabine
Resistance in Bladder Cancer.
J Extracell Vesicles. 2025;14:e70179.
PubMed
Abstract available
J Health Popul Nutr
- LIU F, Han L, Liu S, Wang C, et al
Diseases burden and trends of bladder cancer attributable to behavioral and
metabolic factors among global and Chinese population, 1990-2021: results from
the global burden of disease study 2021.
J Health Popul Nutr. 2025;44:377.
PubMed
Abstract available
J Imaging
- KABANOV D, Rubtsova N, Golbits A, Kaprin A, et al
Radiomics-Based Preoperative Assessment of Muscle-Invasive Bladder Cancer Using
Combined T2 and ADC MRI: A Multicohort Validation Study.
J Imaging. 2025;11:342.
PubMed
Abstract available
J Robot Surg
- HAWKINS DA, Camacho M, Godbole G, Dell'Oro C, et al
Comparing quality of life after robot assisted versus open radical cystectomy: A
systematic review.
J Robot Surg. 2025;19:712.
PubMed
Abstract available
J Urol
- CHUNG D, Kassouf W, Agnihotram R, Alday H, et al
Outcomes Among Rural and Urban Patients with High-risk NMIBC: Results from the
Canadian Bladder Cancer Information System (CBCIS).
J Urol. 2025 Oct 30:101097JU0000000000004836. doi: 10.1097/JU.0000000000004836.
PubMed
Abstract available
Medicina (Kaunas)
- KRAEVSKA E, Popovska S
Analysis of HER2 Expression in Different Histological Subtypes and IHC-Based
Molecular Variants of Muscle-Invasive Bladder Carcinoma.
Medicina (Kaunas). 2025;61:1759.
PubMed
Abstract available
- DAMA M, Yorulmaz EM, Ozcan S, Kose O, et al
AISI, SIRI, and MLR in Predicting Surgical Outcomes After Radical Cystectomy:
Revisiting Inflammatory Risk Markers.
Medicina (Kaunas). 2025;61:1756.
PubMed
Abstract available
Mol Biol Rep
- FUJII N, Hirata H, Ban Y, Oka S, et al
Extracellular vesicles-derived LncRNA MAFG-AS1 predicts clinical response to
pembrolizumab in patients with advanced urothelial carcinoma.
Mol Biol Rep. 2025;53:23.
PubMed
Abstract available
Mol Clin Oncol
- GAO W, Li Y, Fu Z, Gao Z, et al
pQTL Mendelian randomization analysis combined with single-cell sequencing to
identify biomarkers and drug targets for bladder cancer.
Mol Clin Oncol. 2025;23:106.
PubMed
Abstract available
Molecules
- CLOUTIER F, Paquin A, Cloutier M, Oufqir Y, et al
Exploring the Synthesis, Anti-Inflammatory and Anti-Tumor Potential of
4-Maleimidylphenyl-Hydrazide Derivatives.
Molecules. 2025;30:4035.
PubMed
Abstract available
NAR Genom Bioinform
- LOMOIO U, Mazza T, Veltri P, Guzzi PH, et al
E-ABIN: an explainable module for anomaly detection in biological networks.
NAR Genom Bioinform. 2025;7:lqaf135.
PubMed
Abstract available
Nat Rev Urol
- EGGER M, D'Andrea VD, Steiner C, Onochie NO, et al
Optimizing local control in the surgical management of bladder cancer.
Nat Rev Urol. 2025 Oct 30. doi: 10.1038/s41585-025-01098.
PubMed
Abstract available
NPJ Precis Oncol
- LIU Z, Xin P, Wu W, Jin M, et al
ACTG1 driven splicing of P4HB gene enhances EMT and bladder cancer progression.
NPJ Precis Oncol. 2025;9:330.
PubMed
Abstract available
Oncologist
- GRANDE E, Bellmunt J, Hussain SA, Al Mansour MM, et al
Guiding first-line treatment decisions in advanced urothelial carcinoma: a global
survey.
Oncologist. 2025;30:oyaf333.
PubMed
Abstract available
- HUSSAIN S, Carr A, Crabb SJ, Dodhia V, et al
UK multidisciplinary recommendations on use of combination first-line enfortumab
vedotin? and pembrolizumab in advanced urothelial carcinoma.
Oncologist. 2025;30:oyaf220.
PubMed
Abstract available
PLoS One
- LLORT ASENS M, Khan I, Fagerholm SC
beta2-integrins as biomarkers in urothelial cancer.
PLoS One. 2025;20:e0326015.
PubMed
Abstract available
Radiol Clin North Am
- WANG C, Shaish H, Luk L
Bladder Cancer and Vesical Imaging-Reporting and Data System: An Updated Review.
Radiol Clin North Am. 2025;63:923-940.
PubMed
Abstract available
Sci Rep
- SINGHAL S, Singhal S, Gardner KL, Dikshit A, et al
A novel spatial framework to validate arsenic exposure gene expression profiling
in bladder cancer using multiplex FISH and AI-powered digital pathology.
Sci Rep. 2025;15:37925.
PubMed
Abstract available
- PARK JY, Kim J, Kim YJ, Kim SH, et al
Multi-institutional validation of AI models for classifying urothelial neoplasms
in digital pathology.
Sci Rep. 2025;15:37215.
PubMed
Abstract available
- YIN G, Zheng S, Wang J, Hua T, et al
Comprehensive analysis of coagulation-associated gene signature in bladder cancer
diagnosis, prognosis, and immunotherapy.
Sci Rep. 2025;15:37768.
PubMed
Abstract available
Transl Androl Urol
- BEN L, Wang J, Wu P
Mechanistic study of GALNT16 promoting malignant progression and metastasis in
bladder cancer: functional analysis and experimental validation.
Transl Androl Urol. 2025;14:2481-2497.
PubMed
Abstract available
- LV L, Wang J, Li L
En bloc transurethral resection versus conventional transurethral resection for
non-muscle invasive bladder cancer: a systematic review and meta-analysis.
Transl Androl Urol. 2025;14:2593-2605.
PubMed
Abstract available
- ALSALMI OA, Alqurashi TS, Alsalmi BA, Aljohani AI, et al
Awareness, knowledge, and willingness about early detection of bladder cancer in
Saudi Arabia: a cross-sectional study.
Transl Androl Urol. 2025;14:2498-2509.
PubMed
Abstract available
Urol Oncol
- BERNSTEIN AN
Sex-based differences in bladder cancer: Functional, oncologic, and biological
considerations.
Urol Oncol. 2025 Oct 23:S1078-1439(25)00406.
PubMed
- VIERGEVER BJ, Zuidema AC, Jonges T, Van Schelven SJ, et al
Molecular subtyping of advanced bladder cancer patients and patient-derived
organoids based on a 3-marker immunohistochemistry approach to evaluate
chemotherapy sensitivity.
Urol Oncol. 2025 Oct 27:S1078-1439(25)00393.
PubMed
Abstract available
World J Surg Oncol
- HE W, Wang Z, Wang M, Chen Q, et al
Prognostic significance of lymph node yield in pelvic lymph node dissection for
bladder cancer: population-based study.
World J Surg Oncol. 2025;23:405.
PubMed
Abstract available
- SU X, Huang L, Yu Y, Zhang J, et al
LINC01082 inhibits malignant phenotypes of bladder cancer through sponging
miR-1269a.
World J Surg Oncol. 2025;23:402.
PubMed
Abstract available
World J Urol
- LIN J, Fu W, You C, Song X, et al
Updated cost-effectiveness analysis of first-line novel therapies in locally
advanced or metastatic urothelial carcinoma across the UK, US, and China.
World J Urol. 2025;43:657.
PubMed
Abstract available
- DE ANGELIS M, Pellegrino F, Scilipoti P, Longoni M, et al
Real-world impact of cisplatin-based neoadjuvant chemotherapy on bladder cancer
survival: a 20-year study.
World J Urol. 2025;43:636.
PubMed
Abstract available
|
AMEDEO Bladder Cancer is free of charge.
|
FAQ